Bionano Genomics 2025 Q3 Earnings 94.9% EPS Improvement Amid Revenue Growth

Bionano Genomics (BNGO) reported Q3 2025 earnings on Nov 13, 2025, with revenue rising 21.3% to $7.37 million, exceeding 2024’s $6.07 million. The company narrowed its net loss to $8.50 million (from $44.25 million) and reiterated full-year 2025 revenue guidance of $26.0–$30.0 million. Shares fell 8.13% in the latest trading day, reflecting ongoing market skepticism despite improved financials.

Revenue

Instrument sales contributed $1.6 million, while consumables and software drove the majority of revenue growth with $3.8 million and $1.5 million respectively. Total revenue increased by 21.3% year-over-year, reflecting a 7% rise in nanochannel array flowcell sales to 8,390 units and seven new OGM system installations.

Earnings/Net Income

Bionano narrowed its net loss to $8.50 million in Q3 2025, a 80.8% reduction compared to $44.25 million in 2024. Earnings per share (EPS) improved from a loss of $30.92 to $1.59, a 94.9% improvement, driven by disciplined cost management and higher consumables utilization. While the company remains unprofitable, the significant reduction in losses signals progress.

Post-Earnings Price Action Review

The stock price of Bionano Genomics declined 8.13% during the latest trading day and 8.70% over the subsequent week, reflecting heightened volatility. However, a 30-day holding strategy post-earnings yielded a 15.2% return, outperforming typical biotech stock volatility. This short-term positive reaction suggests market optimism about the company’s strategic shift toward consumables and software, despite ongoing financial challenges.

CEO Commentary

CEO Erik Holmlin emphasized the success of Bionano’s strategy to prioritize consumables and software adoption among existing users, noting sustained margins and geographic expansion in Japan. He reiterated confidence in exceeding 25 OGM system installations for 2025 and highlighted the importance of Category I CPT code adoption for long-term growth.

Guidance

Bionano reconfirmed full-year 2025 revenue guidance of $26.0–$30.0 million and initiated Q4 2025 revenue guidance of $7.5–$7.9 million. The company expects new OGM installations to surpass 25, exceeding prior forecasts of 20–25. Forward-looking initiatives include market adoption of OGM and reimbursement support.

Additional News

Bionano completed a $10 million public equity offering in September 2025, extending its cash runway to Q3 2026. CEO Erik Holmlin highlighted the strategic shift from aggressive system installations to driving utilization among “routine users,” with software and consumables now accounting for 72% of revenue. Additionally, the Centers for Medicare & Medicaid Services (CMS) posted preliminary payment determinations for a Category I CPT code for OGM, signaling potential reimbursement progress.

The company’s focus on digital pathology transformation and operational efficiency positions it to address market challenges, though risks like macroeconomic pressures and regulatory changes remain.